Form 4: Revolution Medicines Officer Exercises Options, Sells Shares

Revolution Medicines' Chief Global Commercialization Officer, Anthony Mancini, exercised stock options and subsequently sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

Summary

• Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc., engaged in transactions on March 25, 2026.
• Mancini exercised stock options to acquire 37,450 shares of common stock at an exercise price of $33.62 per share.
• Following the option exercise, Mancini sold a total of 37,450 shares of common stock in multiple transactions at weighted average prices ranging from $93.223 to $97.2071 per share.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025.
• After these transactions, Mancini directly beneficially owns 54,400 shares of common stock, which includes 54,400 Restricted Stock Units.
• Mancini also beneficially owns 112,350 stock options (derivative securities) with an exercise price of $33.62, which vest over time.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine insider activity under a pre-planned 10b5-1 program, indicating no new discretionary selling based on recent material non-public information.

Positives

• The exercise of stock options indicates a belief in the company's value at the exercise price.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which suggests the sales were not based on new, non-public information.

Negatives

• The sale of shares by a high-ranking officer could be perceived negatively by some investors, even if pre-planned.
• The total number of shares sold (37,450) matches the number of shares acquired through option exercise, indicating a strategy to cover taxes and potentially realize gains.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under 10b5-1 plans, are common in the biotechnology sector as executives often receive a significant portion of their compensation in equity. These plans are designed to allow insiders to sell shares without concerns of insider trading, providing liquidity while adhering to regulatory compliance.

Comparison to Industry Standards

• Insider sales to cover option exercise costs and taxes are standard practice across industries, including biotechnology.
• For example, executives at companies like Amgen (AMGN) or Gilead Sciences (GILD) frequently report similar Form 4 transactions where option exercises are immediately followed by sales to manage equity compensation.
• The scale of this transaction for Mr. Mancini is typical for a Chief Global Commercialization Officer at a company of Revolution Medicines' size.

Related Party Transactions

• The transactions represent a related party transaction as they involve an officer of Revolution Medicines, Inc. exercising options and selling company stock.

Stakeholder Impact

• Shareholders may view the sale as a routine liquidity event or, less commonly, as a signal of reduced confidence, though the 10b5-1 plan mitigates the latter.
• Employees are unlikely to experience direct impact, but general sentiment regarding executive stock sales can sometimes influence morale.

Next Steps

• The remaining 112,350 stock options will continue to vest according to the schedule, with full vesting by April 1, 2029 (fourth anniversary of Vesting Commencement Date), subject to continued service.

Key Dates

Recommendation

The filing details routine insider transactions (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 plan. Such transactions are common for executives managing their equity compensation and typically do not signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this disclosure. Investors should focus on the company's operational performance and strategic developments rather than these pre-scheduled sales.

Keywords

Revolution Medicines, RVMD, Anthony Mancini, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Officer Transactions, Biotechnology